{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:57:46Z","timestamp":1781611066834,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Young age has been reported as a patient-related risk factor for chemotherapy-induced nausea and vomiting (CINV). However, there have been few reports of the status of CINV limited to younger patients. In this study, CINV status after cisplatin administration was investigated in young patients with sarcoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective, observational study included patients younger than 65 years with sarcoma who received cisplatin-containing chemotherapy at the Department of Orthopaedic Surgery, Cancer Institute Hospital Ariake, Japan, between January 2011 and December 2020. The evaluated endpoints were the complete response (CR) rate, defined as no emesis and no use of rescue antiemetics, and the no-vomiting rate, defined as no emesis regardless of rescue antiemetic use, in three age groups: children (&lt;\u200915 years), adolescent and young adult (AYA; \u226515 to &lt;\u200940 years), and middle age (MA; \u226540 to \u2264\u200964 years).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty patients in the children group, 32 in the AYA group, and 19 in the MA group were included in the analysis. CR rates overall and in the delayed phase were 20% (4\/20) in the children group, 28.1% (9\/32) in the AYA group, and 42.1% (8\/19) in the MA group. CR rates in the acute phase were 70% (14\/20) in the children group, 78.1% (25\/32) in the AYA group, and 94.7% (18\/19) in the MA group. No-vomiting rates overall and in the delayed phase were 50.0% (10\/20) in the children group, 59.4% (19\/32) in the AYA group, and 78.9% (15\/19) in the MA group. No-vomiting rates in the acute phase were 95.0% (19\/20) in the children group, 96.9% (31\/32) in the AYA group, and 100% (19\/19) in the MA group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Even in patients younger than 65 years, the risk of CINV seemed higher in younger age groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Retrospectively registered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40780-025-00490-x","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T13:44:18Z","timestamp":1759153458000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification of high-risk age groups for cisplatin-induced nausea and vomiting in young patients with sarcoma"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3266-573X","authenticated-orcid":false,"given":"Azusa","family":"Soejima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6637-4433","authenticated-orcid":false,"given":"Koki","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2023-1300","authenticated-orcid":false,"given":"Kazuyoshi","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9517-7283","authenticated-orcid":false,"given":"Wataru","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0767-2606","authenticated-orcid":false,"given":"Takeshi","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Ae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6603-4487","authenticated-orcid":false,"given":"Masakazu","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"issue":"6","key":"490_CR1","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1093\/annonc\/mdx100","volume":"28","author":"G Dranitsaris","year":"2017","unstructured":"Dranitsaris G, Molassiotis A, Clemons M, Roeland E, Schwartzberg L, Dielenseger P, et al. The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann Oncol. 2017;28(6):1260\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdx100.","journal-title":"Ann Oncol"},{"issue":"1","key":"490_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00520-010-1073-9","volume":"20","author":"DL Hilarius","year":"2012","unstructured":"Hilarius DL, Kloeg PH, van der Wall E, van den Heuvel JJG, Gundy CM, Aaronson NK. Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. Support Care Cancer. 2012;20(1):107\u201317. https:\/\/doi.org\/10.1007\/s00520-010-1073-9.","journal-title":"Support Care Cancer"},{"key":"490_CR3","doi-asserted-by":"publisher","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21442.","DOI":"10.3322\/caac.21442"},{"issue":"3","key":"490_CR4","doi-asserted-by":"publisher","first-page":"228","DOI":"10.2174\/157488708785700506","volume":"3","author":"A Sakamoto","year":"2008","unstructured":"Sakamoto A, Iwamoto Y. Current status and perspectives regarding the treatment of osteosarcoma: chemotherapy. Rev Recent Clin Trials. 2008;3(3):228\u201331. https:\/\/doi.org\/10.2174\/157488708785700506.","journal-title":"Rev Recent Clin Trials"},{"issue":"25","key":"490_CR5","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1056\/NEJM198606193142502","volume":"314","author":"MP Link","year":"1986","unstructured":"Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986;314(25):1600\u20136. https:\/\/doi.org\/10.1056\/NEJM198606193142502.","journal-title":"N Engl J Med"},{"issue":"36","key":"490_CR6","doi-asserted-by":"publisher","first-page":"8845","DOI":"10.1200\/JCO.2004.00.5785","volume":"23","author":"S Ferrari","year":"2005","unstructured":"Ferrari S, Smeland S, Mercuri M, Bertoni F, Longhi A, Ruggieri P, et al. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian sarcoma groups. J Clin Oncol. 2005;23(36):8845\u201352. https:\/\/doi.org\/10.1200\/JCO.2004.00.5785.","journal-title":"J Clin Oncol"},{"issue":"4","key":"490_CR7","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1007\/s10157-013-0878-5","volume":"18","author":"O Uemura","year":"2014","unstructured":"Uemura O, Nagai T, Ishikura K, Ito S, Hataya H, Gotoh Y, et al. Creatinine-based equation to estimate the glomerular filtration rate in Japanese children and adolescents with chronic kidney disease. Clin Exp Nephrol. 2014;18(4):626\u201333. https:\/\/doi.org\/10.1007\/s10157-013-0878-5.","journal-title":"Clin Exp Nephrol"},{"issue":"3","key":"490_CR8","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 2013;48(3):452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"490_CR9","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00520-017-3864-8","volume":"26","author":"J Flank","year":"2018","unstructured":"Flank J, Robinson PD, Holdsworth M, Phillips R, Portwine C, Gibson P, et al. Olanzapine for prevention of chemotherapy-induced nausea and vomiting in children and adolescents: a multi-center, feasibility study. Support Care Cancer. 2018;26(2):549\u201355. https:\/\/doi.org\/10.1007\/s00520-017-3864-8.","journal-title":"Support Care Cancer"},{"issue":"8","key":"490_CR10","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1093\/annonc\/mdw228","volume":"27","author":"K Suzuki","year":"2016","unstructured":"Suzuki K, Yamanaka T, Hashimoto H, Shimada Y, Arata K, Matsui R, et al. Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study. Ann Oncol. 2016;27(8):1601\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdw228.","journal-title":"Ann Oncol"},{"issue":"6","key":"490_CR11","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.jpainsymman.2015.12.326","volume":"51","author":"A Molassiotis","year":"2016","unstructured":"Molassiotis A, Lee PH, Burke TA, Dicato M, Gascon P, Roila F, et al. Anticipatory nausea, risk factors, and its impact on chemotherapy-induced nausea and vomiting: results from the Pan European emesis registry study. J Pain Symptom Manage. 2016;51(6):987\u201393. https:\/\/doi.org\/10.1016\/j.jpainsymman.2015.12.326.","journal-title":"J Pain Symptom Manage"},{"issue":"6","key":"490_CR12","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1177\/0300060518765324","volume":"46","author":"A Ruggiero","year":"2018","unstructured":"Ruggiero A, Dell\u2019Aversana G, Carli M, et al. Acute chemotherapy-induced nausea and vomiting in children with cancer: still waiting for a common consensus on treatment. J Int Med Res. 2018;46(6):2149\u201356. https:\/\/doi.org\/10.1177\/0300060518765324.","journal-title":"J Int Med Res"},{"key":"490_CR13","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3389\/fphar.2020.00329","volume":"11","author":"ASM Mosa","year":"2020","unstructured":"Mosa ASM, Hossain AM, Lavoie BJ, Yoo I. Patient-related risk factors for chemotherapy-induced nausea and vomiting: a systematic review. Front Pharmacol. 2020;11:329. https:\/\/doi.org\/10.3389\/fphar.2020.00329.","journal-title":"Front Pharmacol"},{"issue":"4","key":"490_CR14","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/cac2.12410","volume":"43","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Zhao B, Chen G, Chen Y, Liao Z, Zhang H, et al. Validation of different personalized risk models of chemotherapy-induced nausea and vomiting: results of a randomized, double-blind, phase III trial of fosaprepitant for cancer patients treated with high-dose cisplatin. Cancer Commun (Lond). 2023;43(4):246\u201356. https:\/\/doi.org\/10.1002\/cac2.12410.","journal-title":"Cancer Commun (Lond)"},{"issue":"5","key":"490_CR15","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1248\/bpb.b13-00899","volume":"37","author":"N Mukoyama","year":"2014","unstructured":"Mukoyama N, Yoshimi A, Goto A, Kotani H, Ishikawa K, Miyazaki N, et al. An analysis of behavioral and genetic risk factors for chemotherapy-induced nausea and vomiting in Japanese subjects. Biol Pharm Bull. 2014;37(5):683\u20137. https:\/\/doi.org\/10.1248\/bpb.b13-00899.","journal-title":"Biol Pharm Bull"},{"issue":"7","key":"490_CR16","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1200\/JCO.1993.11.7.1269","volume":"11","author":"JH Edmonson","year":"1993","unstructured":"Edmonson JH, Ryan LM, Blum RH, Brooks JS, Shiraki M, Moertel CG, et al. Randomized comparison of doxorubicin alone versus Ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol. 1993;11(7):1269\u201375. https:\/\/doi.org\/10.1200\/JCO.1993.11.7.1269.","journal-title":"J Clin Oncol"},{"issue":"2","key":"490_CR17","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S1470-2045(19)30795-4","volume":"21","author":"H Hashimoto","year":"2020","unstructured":"Hashimoto H, Abe M, Tokuyama O, Mizutani H, Uchitomi Y, Yamaguchi T, et al. Olanzapine 5\u00a0mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(2):242\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(19)30795-4.","journal-title":"Lancet Oncol"},{"issue":"6","key":"490_CR18","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s11096-013-9830-0","volume":"35","author":"TGM Bauters","year":"2013","unstructured":"Bauters TGM, Verlooy J, Robays H, Benoit Y, Laureys G. Emesis control by aprepitant in children and adolescents with chemotherapy. Int J Clin Pharm. 2013;35(6):1021\u20134. https:\/\/doi.org\/10.1007\/s11096-013-9830-0.","journal-title":"Int J Clin Pharm"},{"key":"490_CR19","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines Version 1.2024 Antiemesis [Internet]. 2024 [cited 2024 Aug 3]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf"},{"key":"490_CR20","doi-asserted-by":"publisher","first-page":"e29602","DOI":"10.1002\/pbc.30001","volume":"69","author":"P Patel","year":"2022","unstructured":"Patel P, Hesketh PJ, Burke MJ, et al. Prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric cancer patients: A clinical practice guideline. Pediatr Blood Cancer. 2022;69:e29602. https:\/\/doi.org\/10.1002\/pbc.30001.","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"490_CR21","doi-asserted-by":"publisher","first-page":"e28532","DOI":"10.1002\/pbc.28532","volume":"67","author":"V Radhakrishnan","year":"2020","unstructured":"Radhakrishnan V, Pai V, Rajaraman S, et al. Olanzapine versus Metoclopramide for the treatment of breakthrough chemotherapy-induced vomiting in children: an open-label, randomized phase 3 trial. Pediatr Blood Cancer. 2020;67(9):e28532. https:\/\/doi.org\/10.1002\/pbc.28532.","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"490_CR22","doi-asserted-by":"publisher","first-page":"106","DOI":"10.5863\/1551-6776-30.1.106","volume":"30","author":"M Roberts","year":"2025","unstructured":"Roberts M, Potter T, Wilmot K, et al. Evaluation of olanzapine for the prevention of refractory Chemotherapy-Induced vomiting in pediatric oncology patients. J Pediatr Pharmacol Ther. 2025;30(1):106\u201311. https:\/\/doi.org\/10.5863\/1551-6776-30.1.106.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"5","key":"490_CR23","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1097\/MPH.0000000000002532","volume":"45","author":"JP Meena","year":"2023","unstructured":"Meena JP, Gupta AK, Jat KR, Anandani G, Sasidharan A, Tanwar P. Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting in children: a systematic review and meta-analysis of randomized controlled trials. J Pediatr Hematol Oncol. 2023;45(5):361\u20139. https:\/\/doi.org\/10.1097\/MPH.0000000000002532.","journal-title":"J Pediatr Hematol Oncol"},{"key":"490_CR24","doi-asserted-by":"publisher","unstructured":"Moshayedi M, Salehifar E, Karami H, Hendouei N, Mousazadeh M, Haji SA. Efficacy and safety of adding olanzapine to the standard preventive regimen for chemotherapy-induced nausea and vomiting in children: a randomized double-blind controlled trial. Iran J Pharm Res 2021 Winter;20(1):318\u201326. https:\/\/doi.org\/10.22037\/ijpr.2019.112514.13803","DOI":"10.22037\/ijpr.2019.112514.13803"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00490-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-025-00490-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00490-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:50:22Z","timestamp":1781610622000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40780-025-00490-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["490"],"URL":"https:\/\/doi.org\/10.1186\/s40780-025-00490-x","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"15 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Review Committee for Medical Research of the Cancer Institute Foundation (approval number: 2020-GA-1269) and conducted in compliance with the \u201cEthical Guidelines for Medical and Health Research Involving Human Subjects\u201d. Information about study inclusion was posted on the hospital website, and consent was obtained via the opt-out method.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"83"}}